Spine Market: Pure Plays Continue to Grab Share

Amidst low growth and a potential rebound in the $9 billion global spine market, the pure-play spine companies, including NuVasive, Globus, K2M and LDR, continue to outperform and grab share from the diversified giants. Medtech Insight founder and former CEO Sharon O'Reilly reports on these companies and more from the 2015 North American Spine Society (NASS) conference in Chicago, where the latest news centered around ancillary approaches to fusion, patient-specific tools, robotics, biologics, expandable cages, MIS and cervical discs.

Slow and stable growth is the new mantra for the spine market as the industry enters a mature stage – a welcome change from the turbulence experienced over the past few years. This year’s North American Spine Society (NASS) conference in Chicago was more subdued than past meetings and not rocked by major M&A or IPO announcements or new blockbuster products. (SeeAlso see "Orthopedics: Bracing For Change" - Medtech Insight, 29 May, 2015..) Instead, the buzz centered around ancillary approaches to fusion – the industry’s largest segment accounting for 88% of the total US spine hardware market according to BioMedGPS’ SmartTRAK Financial Dashboard as shown in Exhibit 1. Patient-specific tools, robotics, biologics, expandable cages and, not surprisingly, minimally invasive surgery and cervical discs were the dominant themes of the meeting. The general consensus based on conversations on the NASS 2015 exhibit floor is that the $9 billion global spine market will expand at a slow pace (about 2%), pricing will remain under pressure and the pure-play spine companies (NuVasive Inc., Globus Medical Inc., K2M Group Holdings Inc. and [LDR Spine USA Inc.]/LDR Holding Corp.) will continue to grab share from the diversified giants. (SeeAlso see "Spine Market: Making A Comeback" - Medtech Insight, 30 January, 2015..)

Zimmer Biomet Holdings Inc., SeaSpine Holdings Corp., Integra LifeSciences' public spin-off, and Xtant Medical, formed from the merger of Bacterin International Holdings Inc. and X-spine Systems...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Deals

Roche Diagnostics Day 2025: ‘We Need To Become A Leader In Decentralized Testing’

 

Roche aims to grow its diagnostics sales by mid to high single digits, said CEO of Roche Diagnostics Matt Sause. The company unveiled the Axelios synthesis and sequencing solution and discussed its “long-term commitment” to China, as well as its business strategy for the next five years.

23andMe Purchase Will Let Regeneron Scale Drug Development

 

The consumer genomics firm will operate as a subsidiary, while Regeneron plans to leverage its database for drug discovery and trial design efforts.

Deals Shaping The Medtech And Diagnostics Industries, March 2025

 
• By 

An interactive look at medtech and diagnostics deals made during March 2025. Data courtesy of Biomedtracker.

Roar Of Eargo-hearX Merger Echoes Through US OTC Hearing Aid Market

 

The firms recently announced they will operate as combined company LXE Hearing marketing Eargo’s namesake line and hearX’s Lexie brands. Eargo majority owner Patient Square Capital added $100m to its investment.

More from Business

Handheld Diagnostics: A Resurging Category That is Here to Stay

 

Handheld diagnostics are more powerful, accessible and clinically relevant than ever. Medtech Insight spoke to companies behind such technologies to learn how they work and discuss their commercial models.

Roche Diagnostics Day 2025: ‘We Need To Become A Leader In Decentralized Testing’

 

Roche aims to grow its diagnostics sales by mid to high single digits, said CEO of Roche Diagnostics Matt Sause. The company unveiled the Axelios synthesis and sequencing solution and discussed its “long-term commitment” to China, as well as its business strategy for the next five years.

BD To Shift China-Facing Production, Ramp Up US Output With $2.5B To Counter Tariff Blow

 
• By 

BD is accelerating transitions of product sourcing for China to avoid tariffs. Historically, products like Vacutainer were exported from Sumter, SC, to China, and Flush was shipped from Columbus, NE.